It is a chronic inflammatory disease that can affect the entire body, not just the skin. It is estimated that there are 400,000 to 500,000 patients in the country.

What is 'PASI' in psoriasis treatment?

It is a scoring system used to quantify the severity of psoriasis. PASI90/100 refers to a 90%/100% improvement in symptoms.

What is the main role of biosimilars (follow-on biologics)?

They have equivalent quality, safety, and efficacy to the original biologic medicines, and contribute to reducing patient burden, optimizing healthcare costs, and sustaining the universal health insurance system.

How is the switch from an original biologic medicine to a biosimilar performed?

It is recommended to be conducted with the agreement of the attending physician, based on scientific evidence both domestically and internationally, while considering safety.

Where can this dialogue be viewed?

It is published on the official website of the Japan Biosimilars Council, and the PDF version can also be downloaded.

Role and Expectations of Biosimilars in Psoriasis Treatment (Dialogue: Dr. Akiharu Morita, Nagoya City University)

Published May 22, 2026 7:00 PM ・ Updated Jun 14, 2026 8:09 AM ・ 3 min read ・ Source: PR TIMES

The Japan Biosimilar Association has released an expert dialogue titled 'Role and Expectations of Biosimilars in Psoriasis Treatment' featuring Dr. Akiharu Morita of Nagoya City University.

The Japan Biosimilar Association (Chairman: Tatsuo Kurokawa) has released the 9th installment of its Chairman's Dialogue series on its official website. The theme is 'Role and Expectations of Biosimilars in Psoriasis Treatment.' Dr. Akiharu Morita, Professor of Aging and Environmental Dermatology at Nagoya City University Graduate School of Medicine, and Chairman Tatsuo Kurokawa discuss the current status and challenges of psoriasis treatment, as well as the positioning and future prospects of biosimilars.

Psoriasis is a chronic inflammatory disease, and treatment options have expanded significantly with the advent of biological products. Key points discussed include: - An estimated 400,000 to 500,000 psoriasis patients in Japan. - The advent of biologicals has made 'PASI 90/100 achievement' a realistic goal. Future focus is on 'bio-free' states and reducing patient burdens. - Eliminating regional disparities in medical access is crucial. - Patient-centric and sustainable treatment selection is essential. - Biosimilars contribute to reduced patient burdens, healthcare cost optimization, and the sustainability of the national health insurance system. - Switching from reference biological products should be conducted based on scientific evidence and in consultation with the attending physician.

This dialogue provides general information and is not intended to promote specific drugs or replace medical diagnosis or treatment.

FACT BOX

Source: PR TIMES
Category: News

Role and Expectations of Biosimilars in Psoriasis Treatment (Dialogue: Dr. Akiharu Morita, Nagoya City University)

⚡ Key Points

FACT BOX

Editorial & Verification Standards

FAQ

Cite this article — HOW TO CITE

AI CRAWLER ACTIVITY